Reich v. Haemonetics Corp.

907 F. Supp. 512, 1995 U.S. Dist. LEXIS 18997, 1995 WL 761463
CourtDistrict Court, D. Massachusetts
DecidedDecember 19, 1995
DocketCiv. A. 94-10789-RCL
StatusPublished
Cited by6 cases

This text of 907 F. Supp. 512 (Reich v. Haemonetics Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Reich v. Haemonetics Corp., 907 F. Supp. 512, 1995 U.S. Dist. LEXIS 18997, 1995 WL 761463 (D. Mass. 1995).

Opinion

FINDINGS OF FACT AND CONCLUSIONS OF LAW

LINDSAY, District Judge.

This case involves the interpretation of a provision of the Fair Labor Standards Act (“the FLSA”), 29 U.S.C. § 201 et seq., as applied to a group of employees (called “Business Analysts”) of Haemoneties Corporation (“Haemoneties,” the “company” or the “defendant”). The plaintiff, the Secretary of Labor (the “Secretary” or the “plaintiff’), contends that these Business Analysts do not fall within the “administrative exception” to the overtime provisions of the FLSA, 29 U.S.C. § 213(a)(1), and so are owed back-wages for overtime hours worked. The defendant, Haemoneties, contends that the Business Analysts are exempt from these overtime provisions, and that no back-pay is due. The parties agree that the sole issue in this case is the applicability of the administrative exception to this group of employees.

*513 For the reasons set forth below, this court determines that the Business Analysts are exempt under 29 U.S.C. § 213(a)(1).

I. Findings of Fact

Haemoneties manufactures and sells equipment for the separation of human blood into its components preparatory to reinfusion of the blood into surgical patients. 1 The equipment consists of electronic machinery that processes information and provides power for the collection, cleaning and separation of blood; and single-use utensils (called “disposables”) for the transport and storage of the blood. The machines have a list price of $15,000 to $40,000; the disposables list at $15 to $210. Despite the machines’ higher cost, the majority of Haemoneties’ revenues are derived from the sale of disposables, because of the high volume of disposable sales. Neither machines nor disposables are regularly sold at their list prices. Most sales are negotiated by Haemoneties and the buyer; the price varies depending on the frequency with which the customer purchases disposables, the volume of disposables purchased, the competition in the geographical market in which the customer is situated, and the customer’s potential for growth, as determined by Haemoneties. The company’s customers are hospitals, blood banks, and commercial plasma centers.

The parties stipulated to the following facts, some of which are jurisdictional facts. The Business Analysts are compensated on a salary basis of at least $250 a week, and their primary duty consists of office or nonmanual work. They work an average of 47 hours per week. The Business Analyst position was created on June 1, 1994. Before that date, some of the duties performed by the Business Analysts were performed by “Customer Service Analysts.” The parties disagreed as to the extent of this congruity and its importance.

The Business Analysts’ job is broadly separable into two categories: “structuring deals” and “special projects.” Structuring deals takes more of the Business Analysts’ time on a day-to-day basis and is the more important of the two functions from the company’s point of view. However, as the nature of both aspects of the Business Analyst position is important to the analysis under 11 U.S.C. § 213(a)(1), the court will discuss both.

A Structuring Deals

As mentioned above, the prices for Haemo-neties’ equipment are not predetermined. Although there are standard “list prices” for the equipment, neither the machines nor the disposables customarily, if ever, sell at these prices. Instead, sales are individually negotiated, and the terms of each customer’s deal are different, depending on the customer. Haemoneties’ customers can buy their machines in one of three ways: they may buy them outright, lease them, or buy through a “usage plan.” Under a usage plan, the customer pays for the machine over time by way of a surcharge on the cost of disposables purchased. The majority of Haemoneties’ customers buy their machines through usage plans.

The Business Analysts play an integral role in the process of determining the price Haemoneties will charge each customer for the equipment purchased. If the customer is buying through a usage plan, the Business Analyst is responsible, along with a company sales representative, for structuring the initial usage plan. If the customer wishes to renegotiate the usage plan during the course of the contract (as the typical customer does at least once), the Business Analyst is responsible for renegotiating the terms of the deal. 2 Further, it is the Business Analyst’s *514 responsibility to track a customer’s usage plan to see whether the customer is falling behind (using fewer disposables than predicted, thus paying for the machine more slowly than initially anticipated) or is ahead (using more disposables than predicted, and buying the machine more quickly).

The basic structure of a sales transaction is as follows: the sales representative (whose status under the FLSA is not at issue in this case) negotiates mutually-agreeable terms for a sale with a potential customer, then enters this information into a computerized spreadsheet. The sales representative then sends this spreadsheet to a Business Analyst via electronic mail (“e-mail”). When the Business Analyst opens the e-mail, he or she “unlocks” a second page of the spreadsheet by using a password. The sales representative does not have access to the second page of the spreadsheet.

Information on the second page of the spreadsheet includes the company’s target gross margin for each product, the target revenue for each product, and the difference between the actual and target margins and revenues. This information (which is not input by the Business Analyst, but is pre-programmed into the spreadsheet) allows the Business Analyst to examine the sales representative’s proposed deal in light of Haemo-netics’ revenue goals. Although the Business Analyst plays no role in determining the target revenue and target margin (one witness testified that these were set by Haemo-netics’ Chief Financial Officer or his office), he or she uses this information in deciding whether a proposed deal makes sense for the company. If the Business Analyst finds that this proposed sale does not make sense for the company, he or she may modify various terms in the deal (for example, by changing the kind of machines in the usage plan, or by using different disposables, or by extending or compressing the length of the contract, or by adjusting the prices of machines, disposables, or both) until a satisfactory outcome for the company is found.

The Business Analyst then proposes this modified plan to the sales representative. If the sales representative agrees to the modified plan, the plan is submitted for approval to the Manager of Marketing and Customer Support. Two of such managers testified that they accept the deals recommended by the Business Analysts 90-95% of the time.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Davis v. J.P. Morgan Chase & Co.
587 F.3d 529 (Second Circuit, 2009)
Cooke v. General Dynamics Corp.
993 F. Supp. 56 (D. Connecticut, 1997)
Dambreville v. City of Boston
945 F. Supp. 384 (D. Massachusetts, 1996)
Reich v. John Alden Life Insurance
940 F. Supp. 418 (D. Massachusetts, 1996)
Rodriguez v. Iberia Lineas Aereas De Espana
923 F. Supp. 304 (D. Puerto Rico, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
907 F. Supp. 512, 1995 U.S. Dist. LEXIS 18997, 1995 WL 761463, Counsel Stack Legal Research, https://law.counselstack.com/opinion/reich-v-haemonetics-corp-mad-1995.